Search

Displaying results 4271 - 4280 of 5261 in total
  1. Drug

    TM5614

    go.drugbank.com/drugs/DB16516
    Investigational

    TM5614 is a novel, orally active, plasminogen activator inhibitor 1 (PAI-1) inhibitor[A228788,A228793,]. PAI-1 is a marker of obesity, type 2 diabetes, and metabolic syndrome , and current studies are exploring downstream effects of its ...

  2. Drug

    Hesperetin

    go.drugbank.com/drugs/DB01094
    Investigational

    Hesperetin, in the form of its glycoside [hesperidin], is the predominant flavonoid in lemons and oranges.

  3. Drug

    Frangula purshiana bark

    go.drugbank.com/drugs/DB15478
    Approved

    Mixtures: Herbalax Forte No 70 Tab
  4. Drug

    SQ-109

    go.drugbank.com/drugs/DB05186
    Investigational

    SQ-109 is an orally active, small molecule antibiotic for treatment of pulmonary TB. Currently in Phase I clinical trials, SQ-109 could replace one or more drugs in the current first-line TB drug regimen, simplify therapy, and shorten th...

    Synonyms: N-adamantanyl-N'-geranyl-ethylenediamine
  5. Drug

    Rivoglitazone

    go.drugbank.com/drugs/DB09200
    Investigational

    It is being developed by Daiichi Sankyo Co.

  6. Drug

    Fosinoprilat

    go.drugbank.com/drugs/DB14207
    Experimental

    Fosinoprilat is the active phosphinic acid metabolite of prodrug [fosinopril], which is activated by esterases in vivo. It binds zinc with phosphinic acid group.

  7. Drug

    GLP-1 (7-36) amide

    go.drugbank.com/drugs/DB19258
    Investigational

    GLP-1 (7-36) amide is under investigation in clinical trial NCT01185119 (Effect of GLP-1 on Glucose Metabolism in CNS Assessed by PET).

  8. Drug

    AG0302-COVID19

    go.drugbank.com/drugs/DB16435
    Investigational

    Sponsored by Anges, Inc. in Japan, the AG0302-COVID19 is a DNA-based vaccine that recently completed Phase I/II trials (NCT04527081)[A226813, L30548].

  9. Drug

    VAD-044

    go.drugbank.com/drugs/DB17697
    Investigational

    VAD-044 is an allosteric AKT inhibitor developed by Vaderis Therapeutics AG. It is being investigated for the treatment of Hereditary Hemorrhagic Telangiectasia.[L46098]

  10. Drug

    Magnesium trisilicate

    go.drugbank.com/drugs/DB09281
    Approved

    Magnesium trisilicate is an inorganic compound that is used as an antacid in the treatment of peptic ulcers.